{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-040625","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.623466+00:00","generated_at":"2026-05-23T03:58:52.995831+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bicycle Therapeutics presents positive MT1-MMP imaging data from 12 solid tumor patients at AACR 2025","bullets":["Data from 12 patients validate MT1-MMP as cancer target; BRC tracer showed uptake in primary tumors and metastases.","In lung cancer patient, MT1-MMP-PET showed BRC uptake in primary tumor (SUVmax 6.0) and bone metastases (SUVmax 7.9).","In breast/bladder cancer patient, MT1-MMP-PET revealed higher uptake than CT; IHC confirmed MT1-MMP expression in tumor.","Second BRC molecule targeting EphA2: initial human imaging data expected 2H 2025; company-sponsored trials planned for 2026.","Overall, 12 of 14 patients imaged successfully; results support radiopharmaceutical therapy potential."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-040625","json":"https://secwatch.observer/filing/0001104659-25-040625.json","markdown":"https://secwatch.observer/filing/0001104659-25-040625.md","text":"https://secwatch.observer/filing/0001104659-25-040625.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925040625/0001104659-25-040625-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465925040625/tm2513386d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T03:58:52.995831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}